SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Thomas ED. Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases. J Clin Oncol 1983; 1: 517531.
  • 2
    Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 1829.
  • 3
    Butturini A, Bortin MM, Gale RP. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 1987; 2: 233242.
  • 4
    Fefer A, Sullivan KM, Weiden P, et al. Graft versus leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog Clin Biol Res 1987; 244: 401408.
  • 5
    Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555562.
  • 6
    Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 17201728.
  • 7
    Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 10681073.
  • 8
    Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 23102318.
  • 9
    Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 20412050.
  • 10
    Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: Is T cell dose important in determining biological response? Bone Marrow Transplant 1995; 15: 591594.
  • 11
    Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 1421.
  • 12
    Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22: 16.
  • 13
    Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000; 95: 19181924.
  • 14
    Kean LS, Durham MM, Adams AB, et al. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood 2002; 99: 18401849.
  • 15
    Bradley MB, Sattler RM, Raftopoulos H, et al. Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimen. Biol Blood Marrow Transplant 2002; 8: 453461.
  • 16
    Krishnamurti L, Blazar BR, Wagner JE. Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med 2001; 344: 68.
  • 17
    Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003; 9: 519528.
  • 18
    Schleuning M, Stoetzer O, Waterhouse C, et al. Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. Exp Hematol 2002; 30: 710.
  • 19
    van Besien K, Bartholomew A, Stock W, et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant 2000; 26: 445449.
  • 20
    Amrolia P, Gaspar HB, Hassan A, et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000; 96: 12391246.
  • 21
    Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105: 879885.
  • 22
    Gluckman E, Devergie A, Schaison G, et al. Bone marrow transplantation in Fanconi anaemia. Br J Haematol 1980; 45: 557564.
  • 23
    Gluckman E, Auerbach AD, Horowitz MM, et al. Bone marrow transplantation for Fanconi anemia. Blood 1995; 86: 28562862.
  • 24
    Guardiola P, Socie G, Pasquini R, et al. Allogeneic stem cell transplantation for Fanconi Anaemia. Severe Aplastic Anaemia Working Party of the EBMT and EUFAR. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: S24S27.
  • 25
    Socie G, Gluckman E, Raynal B, et al. Bone marrow transplantation for Fanconi anemia using low-dose cyclophosphamide/thoracoabdominal irradiation as conditioning regimen: Chimerism study by the polymerase chain reaction. Blood 1993; 82: 22492256.
  • 26
    Bitan M, Or R, Shapira MY, et al. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors. Biol Blood Marrow Transplant 2006; 12: 712718.
  • 27
    Tan PL, Wagner JE, Auerbach AD, et al. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. Pediatr Blood Cancer 2006; 46: 630636.
  • 28
    Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005; 36: 215225.
  • 29
    Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991; 80: 428435.
  • 30
    Janka G, Imashuku S, Elinder G, et al. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 1998; 12: 435444.
  • 31
    Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002; 100: 23672373.
  • 32
    Cooper N, Rao K, Gilmour K, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006; 107: 12331236.
  • 33
    Del Toro G, Satwani P, Harrison L, et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004; 33: 613622.
  • 34
    Gomez-Almaguer D, Ruiz-Arguelles GJ, Tarin-Arzaga Ldel C, et al. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transplant 2003; 9: 157161.
  • 35
    Duerst R, Jacobsohn D, Tse WT, et al. Efficacy of reduced intensity conditioning (RIC) with FLU-BU-ATG and allogeneic hematopoietic stem cell transplantation (HSCT) for pediatric ALL. Blood 2004 (abstract); 104: 2314.
  • 36
    Roman E, Cooney E, Harrison L, et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 2005; 11: 7164s7170s.
  • 37
    Manilay JO, Pearson DA, Sergio JJ, et al. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 1998; 66: 96102.
  • 38
    Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412415.
  • 39
    Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 2002; 29: 191195.
  • 40
    Horn B, Baxter-Lowe LA, Englert L, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006; 37: 263269.
  • 41
    Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 13431347.
  • 42
    Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 10711078.
  • 43
    Nagler A, Aker M, Or R, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 2001; 29: 362370.
  • 44
    Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 19781985.
  • 45
    Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: Prevention and therapy. Transpl Infect Dis 1999; 1: 165178.
  • 46
    Einsele H, Ehninger G, Steidle M, et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 16721678.
  • 47
    Uharek L, Hilbers U, Hartung G, et al. Cellular immunotherapy with alloreactive NK cells: Promising results of a phase I/II study investigating the use of ex-vivo activated donor CD3-CD56+ NK cells after transplantation of highly purified HLA-haplotype mismatched stem cell grafts in patients. Onkologie 2003 (abstract); 26: 38.
  • 48
    Koehl U, Sorensen J, Esser R, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33: 261266.
  • 49
    Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 18351838.
  • 50
    Slavin S, Morecki S, Shapira M, et al. Immunotherapy using rIL-2 activated mismatched donor lymphocytes positively selected for CD56+ for the treatment of resistant haematologic malignancies after stem cell transplantation. Bone Marrow Transplant 2004 (abstract); 33: S174.
  • 51
    Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156162.
  • 52
    Shenoy S, Grossman WJ, DiPersio J, et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 2005; 35: 345352.
  • 53
    Storb RF, Champlin R, Riddell SR, et al. Non-myeloablative transplants for malignant disease. Hematol Am Soc Hematol Educ Program 2001; 375391.